Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Oct 24 2011
Weekly update on recommendation, target price, and earnings forecast changes.
Neuren Pharma Could Be The Only One
Oct 21 2011
The lead compound of Neuren Pharmaceuticals is being developed to treat brain injuries and with no current competition in the market Bell Potter sees upside from any success.
Significant Upside Potential For GI Dynamics
Oct 19 2011
GI Dynamics is developing the EndoBarrier product for use in treating type II diabetes and obesity and Bell Potter sees significant upside potential in the stock.
Treasure Chest: Biotech Buzz
Oct 18 2011
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. As the Pharmaxis share price goes for a run, RBS Morgans reports QRxPharma is confident a partnering deal will be signed by Christmas.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Oct 10 2011
Weekly update on recommendation, target price, and earnings forecast changes.
News Flow For Mesoblast Remains Positive
Sep 29 2011
Two positive announcements this month strengthen the Mesoblast story in the view of Bell Potter. The broker retains a Buy rating on the stock.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Sep 26 2011
Weekly update on recommendation, target price, and earnings forecast changes.
Phosphagenics Gets Under The Skin
Sep 21 2011
Phosphagenics continues to develop its TPM drug patch delivery technology and Bell Potter sees this as a key advantage for the company in breaking into sizable markets.
Cochlear’s Problems Sound Deep
Sep 21 2011
After a 25% drop, Cochlear’s risk may still be to the downside as another broker downgrades to Sell.
Top Ten Weekly Recommendation, Target Price, Earnings Forecast Changes
Sep 19 2011
Weekly update on recommendation, target price, and earnings forecast changes.
